Posted On: 08/26/2014 2:31:49 PM
Post# of 30070
Hi sportscard,
One thing that I think is interesting in regards to Lympro that Gerald had mentioned as a result of his recent meetings and conferences was that various companies had previously known about Lympro and was wondering what happened to it. IMHO, the fact that it stuck in some companies' memory and they were curious as to its present status seemingly means that multiple companies have an interest. Also, AMBS is a company that wants to ensure that they have the science and data to back Lympro before anything else. With this approach, I think they add value to Lympro rather than premature hype as done with other companies.
One thing that I think is interesting in regards to Lympro that Gerald had mentioned as a result of his recent meetings and conferences was that various companies had previously known about Lympro and was wondering what happened to it. IMHO, the fact that it stuck in some companies' memory and they were curious as to its present status seemingly means that multiple companies have an interest. Also, AMBS is a company that wants to ensure that they have the science and data to back Lympro before anything else. With this approach, I think they add value to Lympro rather than premature hype as done with other companies.
(0)
(0)
